Prontosan Versus Saline in the Cleansing of Chronic Leg Ulcers in Diabetic Patients
This study is currently recruiting participants.
Verified August 2012 by B. Braun Medical Inc.
Sponsor:
B. Braun Medical Inc.
Information provided by (Responsible Party):
B. Braun Medical Inc.
ClinicalTrials.gov Identifier:
NCT01554644
First received: March 6, 2012
Last updated: August 30, 2012
Last verified: August 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a randomized controlled double blinded study involving two (2) investigational sites in the United States. All subjects (n=40) will receive either Prontosan Wound Irrigation Solution and Gel treatment or standard of care treatment (0.9% saline) and placebo gel. This is a 12-week study.
| Condition | Intervention |
|---|---|
|
Diabetic Complications |
Device: Prontosan Device: Saline |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | A Randomized, Double-Blind Exploratory Pilot Study Comparing Prontosan(TM) Versus Saline in the Cleansing of Chronic Leg Ulcers in Diabetic Patients |
Resource links provided by NLM:
Further study details as provided by B. Braun Medical Inc.:
Primary Outcome Measures:
- Relative (%) area wound size change versus baseline in respondents to treatment following a 12-week treatment period [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Change in absolute wound area dimensions [ Time Frame: 12-week treatment period ] [ Designated as safety issue: No ]
- Identification of bacteria present on wound bed at baseline and follow-up [ Time Frame: 12-week treatment period ] [ Designated as safety issue: No ]
- Relative change in bacterial load during treatment period [ Time Frame: 12-week treatment period ] [ Designated as safety issue: No ]
- Change in wound margins determined by color photography [ Time Frame: 12-week treatment period ] [ Designated as safety issue: No ]
- Number of "non-responders" as measured by wound size change (<50% relative wound size reduction [ Time Frame: 12-week treatment period ] [ Designated as safety issue: No ]
- Change of clinical wound infection during treatment period [ Time Frame: 12-week treatment period ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 40 |
| Study Start Date: | March 2012 |
| Estimated Study Completion Date: | October 2012 |
| Estimated Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Prontosan Solution and Gel
ProntosanTM Wound Irrigation Solution (PHMB 0.1%, Betaine 0.1%) and ProntosanTM Wound Gel (PHMB 0.1%, Betaine 0.1%)
|
Device: Prontosan
Prontosan(TM) Wound Irrigation Solution (PHMB 0.1%, Betaine 0.1%) and Prontosan(TM) Wound Gel (PHMB 0.1%, Betaine 0.1%). Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
Other Name: Double-blind intervetion; Active/placebo comparator unknown.
|
| Placebo Comparator: Saline Solution and Inert Gel |
Device: Saline
Saline Wound Irrigation Solution and inert Wound Gel. Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
Other Name: Double-blind intervetion; Active/placebo comparator unknown.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or female diabetic (type I or II) patients ≥ 18 years of age.
- Diabetic ulcer(s) present for ≥ 4 weeks located below the knee.
- A total surface area of ≥ 3 cm2 and ≤ 16 cm2.
- Willingness to wear an off-loading device if medically indicated (e.g., DH shoe or Walker).
Exclusion Criteria:
- Pregnant women and nursing mothers.
- Uncontrolled diabetes as defined by glucose levels >225 mg/dl.
- HbA1c ≥ 12%.
- Subjects with a wound infection.
- Subjects receiving antibiotic therapy within 14 days of enrollment.
- Subject with history of or clinical evidence of: Cardiac insufficiency (NYHA functional classification IV), angina pectoris (CCS functional classification IV), unstable pulmonary, renal, hepatic, endocrine or hematologic disease as determined by the Investigator (serum creatinine of > 3.0; transaminase or alkaline phosphatase levels equal to or greater than 5 times the upper limit) malnutrition (albumin < 2.5 g/dL).
- Peripheral arterial occlusive disease with a non-palpable pulse on both dorsal pedial and the posterior tibial artery.
- Presence of gangrene.
- Active rheumatic or collagen vascular disease (including rheumatoid arthritis, scleroderma, and systemic lupus erythematosus)
- Subjects that have been diagnosed with HBV, HVC, AIDS or are HIV positive.
- Osteomyelitis diagnosed by x-ray, bone biopsy, or other radiological procedure within 90 days prior to Screening Period.
- Active radiation therapy below the hip.
- Subject currently receiving, or has received oral or parenteral corticosteroids, immunosuppressive or cytotoxic agents within 30 days prior to Baseline Visit (Visit 1, Week 0) or is anticipated to require such agents during the course of the study.
- Current participation or participation in another investigational drug or medical device study within the last 30 days.
- Subjects who test positive for alcohol and or illicit drug use.
- Subjects who are unable to comprehend or comply with study requirements or ability to sign an informed consent.
- Subjects, who in the opinion of the Investigator would not be a suitable candidate for this study (reason for exclusion needs to be documented).
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01554644
Locations
| United States, California | |
| University of California San Diego | Recruiting |
| San Diego, California, United States, 92130 | |
| Contact: MaryBeth Tyler 619-543-7200 mtyler@ucsd.edu | |
| Principal Investigator: Gerit Mulder, DPM | |
| United States, Illinois | |
| University of Illinois Chicago | Recruiting |
| Chicago, Illinois, United States, 60612 | |
| Contact: Audrey Sui 312-413-7756 asui2@uic.edu | |
| Principal Investigator: William Ennis, DO | |
| Sub-Investigator: Malgorzata Plummer, MD | |
| Sub-Investigator: Igor Altman, DO | |
Sponsors and Collaborators
B. Braun Medical Inc.
Investigators
| Principal Investigator: | William Ennis, DO | University of Illinois Chicago |
| Principal Investigator: | Gerit Mulder, DPM | University of California, San Diego |
More Information
No publications provided
| Responsible Party: | B. Braun Medical Inc. |
| ClinicalTrials.gov Identifier: | NCT01554644 History of Changes |
| Other Study ID Numbers: | OPM-I-H-0910 |
| Study First Received: | March 6, 2012 |
| Last Updated: | August 30, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by B. Braun Medical Inc.:
|
Cleansing Chronic Leg Ulcers Diabetic Patients |
Additional relevant MeSH terms:
|
Leg Ulcer Ulcer Skin Ulcer Diabetes Complications |
Skin Diseases Pathologic Processes Diabetes Mellitus Endocrine System Diseases |
ClinicalTrials.gov processed this record on May 16, 2013